NCT05800327View on ClinicalTrials.gov

A Two-Stage Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics and Immunogenicity of Various Doses of Levilimab When Administered Intravenously and Subcutaneously to Healthy Subjects and Subjects With Active Rheumatoid Arthritis

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

261

Participants

Timeline

Start Date

December 7, 2022

Primary Completion Date

September 30, 2024

Study Completion Date

December 31, 2027

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Levilimab

Subcutaneous or intravenous injection of levilimab with placebo.

Trial Locations (1)

Unknown

X7 Clinical Research, Saint Petersburg

Sponsors

Lead Sponsor

Biocad
All Listed Sponsors
lead

Biocad

INDUSTRY

NCT05800327 - A Two-Stage Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics and Immunogenicity of Various Doses of Levilimab When Administered Intravenously and Subcutaneously to Healthy Subjects and Subjects With Active Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter